Literature DB >> 501215

Decreased hepatic microsomal reserve in patients with cirrhosis. Studies using aminopyrine as model drug.

E Piken, G W Hepner.   

Abstract

It is unclear whether hepatic drug metabolism which is decreased in patients with liver disease, can be stimulated by enzyme-inducing drugs. Hepatic microsomal reserve, defined as the difference between the basal and phenobarbital-stimulated ABT, was therefore studied in eight healthy control subjects and 12 patients with stable alcoholic cirrhosis. The ABT increased significantly (p less than 0.01) from a basal value of 6.1% +/- 0.8 (mean +/- S.D.) to 8.9% +/- 0.8 in the eight control subjects after phenobarbital ingestion. In the 12 patients with alcoholic cirrhosis the basal ABT was 2.9% +/- 1.5 and did not change significantly after phenobarbital ingestion, when the value was 3.0% +/- 1.6. A small increase in the ABT occurred after phenobarbital ingestion in five of the patients with alcoholic cirrhosis, but in no patient did this increase bring the ABT within normal limits. We conclude that in many patients with stable alcoholic cirrhosis aminopyrine metabolism is decreased and cannot be corrected by treatment with phenobarbital.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501215

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

1.  Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism.

Authors:  M Døssing; H Pilsgaard; B Rasmussen; H E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases.

Authors:  S Pauwels; A P Geubel; C Dive; C Beckers
Journal:  Dig Dis Sci       Date:  1982-01       Impact factor: 3.199

3.  [14C]Aminopyrine breath test in chronic liver disease: preliminary diagnostic implications.

Authors:  A V Burnstein; J T Galambos
Journal:  Dig Dis Sci       Date:  1981-12       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.